芪参益气滴丸联合利拉鲁肽对老年2型糖尿病合并冠心病患者血糖、心功能及T细胞亚群的影响  

Effect of Qishenyiqi Pills Combined with Liraglutide on Blood Glucose,Cardiac Function and T Cell Subset of Elderly Patients with Type 2 Diabetes Combined with Coronary Heart Disease

作　　者：包秋红[1] 张勇[1] 贾海玉[1] 曹中朝[1] 孙慧[1] BAO Qiu-hong;ZHANG Yong;JIA Hai-yu;CAO Zhong-chao;SUN Hui(The First Ward of Geriatric Medical Center,Affiliated Hospital of Inner Mongolia Medical University,Hohhot,Inner Mongolia,010059,China)

机构地区：[1]内蒙古医科大学附属医院老年医学中心一病区,内蒙古呼和浩特市010059

出　　处：《现代生物医学进展》2020年第20期3897-3901,共5页Progress in Modern Biomedicine

基　　金：内蒙古自治区卫生厅医疗卫生科研计划项目(2013264);内蒙古医科大学青年创新基金项目(YKD2016QNCX026)。

摘　　要：目的:探讨芪参益气滴丸联合利拉鲁肽对老年2型糖尿病合并冠心病患者血糖、心功能及T细胞亚群的影响。方法:选择2017年1月到2019年6月我院收治的老年2型糖尿病合并冠心病患者105例,依照随机数字表法分为对照组(52例)和观察组(53例)。两组均给予常规治疗,对照组在常规治疗的基础上给予利拉鲁肽治疗,观察组在对照组基础上给予芪参益气滴丸治疗,两组均连续给予治疗8周。观察两组临床疗效,比较两组治疗前后血糖指标[空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbAlc)],心功能[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、舒张早期最大峰值速度/舒张晚期最大峰值速度(E/A)]及外周血T细胞亚群CD4+、CD8+、CD4+/CD8+水平。记录两组治疗过程中的不良反应情况。结果:观察组的临床总有效率为96.23%(51/53),高于对照组的82.69%(43/52)(P<0.05)。治疗后,两组FPG、2hPG及HbAlc水平均较治疗前降低(P<0.05),且观察组低于对照组(均P<0.05);LVEF、E/A均升高,LVEDD降低(均P<0.05),观察组LVEF、E/A、LVEDD的改善情况均优于对照组(P<0.05);CD4+、CD4+/CD8+水平均高于治疗前(P<0.05),同时观察组CD4+、CD4+/CD8+水平均高于对照组(P<0.05),两组治疗前后CD8+均无明显变化(P>0.05)。治疗期间,观察组的不良反应发生率为9.43%(5/53),对照组为9.62%(5/52),两组比较差异无统计学意义(x2=0.001,P=0.975)。结论:芪参益气滴丸联合利拉鲁肽治疗老年2型糖尿病合并冠心病的临床疗效较好,有助于改善患者血糖水平和心功能,提高机体免疫功能,且安全性较好。Objective: To explore the effect of qishenyiqi pills combined with liraglutide on blood glucos, cardiac function and T cell subset of elderly patients with type 2 diabetes combined with coronary heart disease. Methods: 105 cases of elderly patients with type2 diabetes combined with coronary heart disease in our hospital from 2017 January to July 2019 were selected. According to the random indicator method, they were divided into the control group(n=52 cases) and the observation group(n=53 cases). Both groups were given routine treatment, patients of the control group were treated with liraglutide on the basis of the conventional treatment, while the observation group were treated with qishenyiqi pills combined with liraglutide on the basis of the control group. The two groups were treated for8 weeks. Clinical curative effect of the two groups was observed. The blood sugar index [fasting plasma glucose(FPG), 2 h postprandial blood glucose(2 hPG), glycosylated hemoglobin(HbAlc)], cardiac function [left ventricular ejection fraction(LVEF), left ventricular end-diastolic diameter(LVEDD), the maximum peak early diastolic velocity/late diastolic peak velocity(E/A) largest] and peripheral blood T cell subsets CD4^+, CD8^+and CD4^+/CD8^+levels of the two groups before and after treatment were compared. The adverse reactions of the two groups during treatment were recorded. Results: Total effective rate of observation group was 96.23%(51/53), which was higher than 82.69%(43/52)of the control group(P<0.05). After treatment, the FPG, 2 hPG, HbAlc of the two groups were lower than those before treatment(P<0.05). And those of the observation group were lower than those of the control group(all P<0.05). LVEF and E/A were increased, while LVEDD was decreased(all P<0.05). The improvement of LVEF, E/A and LVEDD of the observation group were better than those of the control group(P<0.05). CD4^+and CD4^+/CD8^+levels were higher than those before treatment(P<0.05).Meanwhile, CD4^+and CD4^+/CD8^+levels of the observation group were h

关 键 词：2型糖尿病 冠心病 芪参益气滴丸 利拉鲁肽 血糖 心功能 T细胞亚群 疗效 

分 类 号：R587.2[医药卫生—内分泌] R242[医药卫生—内科学]